Mobilized Peripheral Blood Leukopaks

Your source for quality fresh and cryopreserved human cells

Mobilized leukopak collected through donor apheresis after G-CSF and plerixafor stimulation, showing high CD34+ stem cell yield for advanced cell and gene therapy research.

Human Mobilized Peripheral Blood Leukopaks are collected from healthy IRB consented donors that are injected with Granulocyte-Colony Stimulating Factor (G-CSF aka Neupogen®), Plerixafor (aka Mozobil®), or a combination of Plerixafor and G-CSF, which increases circulating leukocytes and stimulates the bone marrow to produce a large number of hematopoietic and progenitor stem cells and mobilizes these cells into the bloodstream, allowing for enriched CD34+ hematopoietic stem cells from a single donor as compared to traditional Leukopaks. Collecting CD34+ stem cells from a single donor eliminates donor-to-donor variation, allows scalability of stem cell studies, and decreases same cell variability. Mobilized Leukopaks are ideal for stem cell studies relating to regenerative medicine, immunotherapy, and transplant therapy.

Why Choose Mobilized Leukopaks from CGT Global

  • High CD34+ cell yields – Up to 20×10⁹ total nucleated cells (TNCs) per leukopak

  • Consistent donor performance – Reduced donor-to-donor variability

  • Ready for translational research – From preclinical to GMP-grade applications

  • Rapid fulfillment – Same-day collection and shipping from Boston, Philadelphia, and Folsom

  • Customizable mobilization – Choose between G-CSF, Plerixafor, or combination mobilization protocols

Customizable mobilization – Choose between G-CSF, Plerixafor, or combination mobilization protocols. Compare mobilization strategies and suppliers in our Mobilized Leukopak Buyers Guide.

Donor Mobilization and Collection Process

Optimized Mobilization for Maximum CD34+ Yield

Each mobilized leukopak is collected from healthy, IRB-consented donors under FDA and AABB standards. Donors receive Granulocyte Colony-Stimulating Factor (G-CSF, Neupogen®) and/or Plerixafor (Mozobil®) to increase circulating stem and immune cells. Using FDA-approved apheresis systems, we harvest high-TNC, high-viability leukopaks ideal for downstream applications.

Key Process Features

  • FDA-registered and CLIA-certified facilities

  • IRB-approved donor recruitment and screening

  • Optional mobilization customization (G-CSF, Plerixafor, combo)

  • Closed-system processing available for GMP applications

BROWSE ALL

Popular Mobilized Peripheral Blood Leukopaks

Fresh Mobilized Leukopaks | G-CSF

Fresh Mobilized Leukopaks | G-CSF + Plerixafor

Fresh Mobilized Leukopaks | Plerixafor

Your Cells, Your Way!

HIGH-QUALITY MOBILIZED LEUKOPAKS

Cell-rich Mobilized Leukopaks are extracted using an FDA-approved apheresis machine. Once collected, Mobilized Leukopaks are sent out on the day of collection to ensure you receive a fresh product.

 

  • 2x1010 TNCs/full bag
  • Enriched CD34+ cells
  • Highly-enriched PBMCs
  • ≥90% viability
  • HBV, HCV, HIV negative
  • IRB approved

DONOR SELECTION

  • Extensive donor pool
  • Specific donor demographics (age, weight, ethnicity, etc.)
  • Donor lifestyle characteristics (BMI, smoker/non-smoker, etc.)
  • Medical history (allergies, medications, etc.)
  • HLA, RhD, and ABO typing available
  • Additional infectious disease screening (CMV, etc.)
  • Much more....

CELL COLLECTION/PROCESSING

  • Special processing procedures available
  • Different mobilization agents available

EXPEDIENCY FROM ORDER TO DELIVERY

  • Custom media and buffer
  • Customizable packaging options
  • Cryo shipping available
  • FedEx®, World Courier®, UPS®
  • Same day delivery in select cities

Frequently Asked Questions

A Mobilized Leukopak is a leukopak collected from a healthy, IRB-consented donor after stimulation with mobilizing agents such as G-CSF (Neupogen®) and/or Plerixafor (Mozobil®). These agents increase the number of circulating CD34+ hematopoietic stem and progenitor cells (HSPCs) in peripheral blood. As a result, mobilized leukopaks provide a significantly higher yield of stem and immune cells compared to standard leukopaks, making them ideal for cell and gene therapy research, CAR-T development, and regenerative medicine applications.

Standard leukopaks are collected from non-mobilized donors, providing a balanced mix of immune cells like T cells, B cells, NK cells, and monocytes.
Mobilized leukopaks, however, are enriched for CD34+ hematopoietic stem cells due to donor mobilization with G-CSF or Plerixafor. This enrichment allows for:

  • Greater CD34+ cell recovery and consistency from a single donor

  • Improved scalability of research and manufacturing processes

  • Reduced donor-to-donor variability

CGT Global offers mobilized leukopaks collected using:

  • G-CSF (Granulocyte Colony-Stimulating Factor, Neupogen®)

  • Plerixafor (Mozobil®)

  • G-CSF + Plerixafor combination protocols

Each mobilization method can be tailored to your study’s requirements. Combination mobilization generally provides the highest CD34+ enrichment and total nucleated cell (TNC) counts.

Mobilized leukopaks deliver a high concentration of CD34+ hematopoietic stem cells, which are essential for:

  • Stem cell differentiation and expansion studies

  • Gene editing and transduction research

  • CAR-T and CAR-NK therapy development

  • Hematopoietic reconstitution and transplant modeling

Researchers prefer mobilized products for consistent, high-yield CD34+ starting material that supports reproducible results in both preclinical and GMP-grade studies.

Typical Mobilized Leukopaks from CGT Global yield up to 20×10⁹ total nucleated cells (TNCs) per full bag, with CD34+ cell counts significantly higher than in non-mobilized collections. Actual yield may vary based on donor response, mobilization agent, and collection parameters.

Yes. CGT Global offers both Research-Use Only (RUO) and GMP-compliant Mobilized Leukopaks. GMP collections are performed under FDA-registered, CLIA-certified facilities with full documentation, chain of custody, and regulatory support for clinical manufacturing, IND-enabling studies, and early-phase trials.

Absolutely. CGT Global maintains an extensive donor registry and supports custom donor selection, including:

  • Demographics: age, gender, ethnicity, BMI

  • HLA, ABO, and RhD typing

  • Medical history and lifestyle characteristics

  • Additional screenings (e.g., CMV, Hepatitis, HIV, and other pathogens)

This customization enables precise donor matching and study reproducibility.

Our Mobilized Leukopaks consistently maintain ≥90% cell viability and are HBV, HCV, and HIV negative. All donors are IRB-approved and screened according to FDA and AABB standards. Each leukopak is processed using FDA-approved apheresis systems, ensuring maximum cell recovery and quality.

Yes. CGT Global provides:

  • Fresh Mobilized Leukopaks — collected and shipped on the same day for time-sensitive applications.

  • Cryopreserved Mobilized Leukopaks — processed immediately after collection to preserve high cell viability and recovery post-thaw.

Cryopreserved options are ideal for long-distance shipping or batch standardization across experiments.

Mobilized Leukopaks are shipped via FedEx®, UPS®, or World Courier®, with same-day delivery available in select U.S. cities near our facilities (Boston, Philadelphia, and Folsom). Cryopreserved shipments are packaged in validated cryoshippers to maintain cold chain integrity and viability during transit.

Yes. We offer extensive customization, including:

  • Choice of mobilization agent (G-CSF, Plerixafor, or both)

  • Custom buffers, media, or cryoprotectants

  • Aliquoting and packaging by desired TNC or CD34+ cell count

  • Closed-system processing for GMP studies

  • Custom cryo-shipping configurations

For fresh leukopaks, collections are typically scheduled within days, with same-day processing and shipment. Cryopreserved mobilized leukopaks are available from inventory or can be prepared to order within 1–2 weeks, depending on customization.